Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
52-week range
$19.05 – $32.56
92% from low
No one on the platform currently holds CPRX.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 2,347,477 | $58.1M |
Auto-close: position no longer at broker (broker-quote-cache).
in FID 401k →No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
$CPRX Thanks to everyone for all that professional comments. I was 14 years on that message board. My Investment is now in Santhera (SANN.SW), could be a next takeover (Owner of the Agamree Licence) . GLTA
View on StockTwits ↗$CPRX @DLAT94 Anorher one I sold way too early. But the pick was good. Congrats longs!
View on StockTwits ↗$CPRX we all were looking for this outcome. Been with this group for the better part of the last 10 years plus. I tank you all and I am super happy that many longs got to enjoy now the fruits of patience CPRX gave us. A good friend of mine worked at CPRX and introduced me to it when it was below $1. I can only thank him. So long all!
View on StockTwits ↗$CPRX thank you cprx management I got in around $3 and never looked back. Wonderful company run beautifully we had many tough times and scary moments but you guys made it through and brought us here. I wish every investment could be as perfect as what you guys have done here. I will miss y’all. ❤️
View on StockTwits ↗$CPRX ty CPRX I tried to look at this account on Robinhood yesterday and it was gone but I had money in my account. Try powder for crypto. Sad and happy at the same time
View on StockTwits ↗$CPRX Now that the SEC today issued its official notice that Catalyst has been removed from the NASDAQ Exchange, I do not know how much longer this community will remain in existence here. So, I want to say that I will miss this group and the engaging posts that have occurred through the many years I have been a shareholder and participant here. I wish the very best to each and every one of you as shareholders and in your personal lives. It has been my pleasure to get to know many of you here and outside of this group. Take care everyone.
View on StockTwits ↗$CPRX Well I guess this is it. Congrats longs I hope to see almost all of you in another stock. Where are you all putting your money these days? Best of luck to you all.
View on StockTwits ↗SEI Stock Jumps 5% After-Hours As S&P 600 Inclusion Sparks Buying $SEI $CPRX https://stocktwits.com/news/equity/markets/sei-stock-jumps-after-hours-as-sandp-600-inclusions-sparks-buying/cZmAZYNR7Fc
View on StockTwits ↗$CPRX / Angelini Pharma – Shareholder Vote $CPRX
View on StockTwits ↗$CPRX this keeps heading higher and higher. Fuck I never got in at when it was sub 10 LOL I wished you boys good luck a few times over the last couple years and it keep going. Congrats , nice steady as she goes
View on StockTwits ↗$CPRX did anyone receive anything about the virtual meeting to vote on the merger?
View on StockTwits ↗$CPRX https://www.stocktitan.net/sec-filings/CPRX/defm14a-catalyst-pharmaceuticals-inc-merger-proxy-statement-91233ea639e8.html
View on StockTwits ↗$CPRX Catalyst Pharmaceuticals (CPRX) may not be the wildest biotech name on Wall Street, but that may be its biggest advantage. With profits, revenue, and rare disease exposure, this small-cap healthcare stock offers a more stable twist on biotech investing. https://biotechhealthx.com/biotech-news/is-catalyst-pharmaceuticals-cprx-a-smart-rare-disease-stock-to-buy-for-long-term-growth/
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $635M | +9.7% | $1.95 | $1.83–$2.07 | 16.1× | 2 |
| 2027 | $718M | +13.0% | $2.41 | $2.11–$2.60 | 13.1× | 3 |
| 2028 | $792M | +10.3% | $2.58 | $2.52–$2.62 | 12.2× | 1 |
| 2029 | $877M | +10.8% | $2.73 | $2.67–$2.77 | 11.5× | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 7 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-05-11 | $0.64 | $0.52 | -18.8% |
| 2026-02-25 | $0.42 | $0.68 | +61.9% |
| 2025-11-05 | $0.51 | $0.68 | +33.3% |
| 2025-08-06 | $0.58 | $0.68 | +17.2% |
| 2025-05-07 | $0.53 | $0.68 | +28.3% |
| 2025-02-26 | $0.32 | $0.70 | +118.7% |
| 2024-11-06 | $0.49 | $0.57 | +16.3% |
| 2024-08-07 | $0.42 |
| $0.56 |
| +33.3% |
| +0.66% |
| $2.8B |
| — |
| CDTXCidara Therapeutics, Inc. | $221.38 | +0.00% | $5.6B | — |
| IDYAIDEAYA Biosciences, Inc. | $36.24 | +0.55% | $3.4B | — |
Source: Financial Modeling Prep · peers by sector/industry